COMPANY

Axonis Therapeutics

Axonis Therapeutics has received NIH funding, most recently in fiscal 2024 for the project “Development of Oral KCC2 Potentiator AXN-027 as a Novel Anti-Epileptic Drug for Mesial Temporal Lobe Epilepsy”. From public records Source · Oct 12, 2026

Keywords: neurology

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · $115M · announced Oct 30, 2024 Company release ↗
Source quote
- Oct 30, 2024 · Company release ↗
  “– Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing”

Raises announced in these releases: $115M disclosed.

From the company’s own releases; this list is partial. All raises and deals